Pre-Operative Window of ET to Inform RT Decisions (POWER II)

Status: RECRUITING

Eligibility Criteria

Age: 65 years and over

This study is NOT accepting healthy

Healthy Volunteers: volunteers

Inclusion Criteria (summary): * Diagnosis of ER+, PR +/-, and HER2- non amplified invasive breast cancer and clinically negative nodes * ECOG performance status 0-2 * Females, aged ≥ 65 years * Patient is eligible for BCS and opted for BCS * Patient is a candidate for radiation therapy * Patient is a candidate for endocrine therapy (tamoxifen or an aromatase inhibitor) * Ability to take oral medication and be willing to adhere to endocrine therapy for the 3-month period prior to BCS * Agreement to adhere to Lifestyle Considerations (details in protocol) throughout study duration * Provision of signed and dated informed consent form * Stated willingness to comply with all study procedures and availability for the duration of the study

---

Exclusion Criteria:

* Bilateral synchronous breast cancer * Multicentric disease * Prior use of SERMS or aromatase inhibitors * History of ipsilateral breast radiation therapy * Has a known additional malignancy that is progressing and/or requires active treatment with cytotoxic chemotherapy or radiation therapy. Malignancies deemed stable and low risk for complication per investigator's judgment may be allowed after discussion with multi-site PI. * Current or planned use of a strong CYP2D6 inhibitor (e.g., Fluvoxamine, Paroxetine) and is not able to receive an endocrine therapy agent that does not use the CYP2D6 pathway.

Conditions & Interventions

Interventions:

DRUG: Tamoxifen, Letrozole, Anastrozole, or Exemestane

Conditions:

Breast Cancer Female

Keywords:

breast cancer, endocrine therapy, radiation, letrozole, anastrozole, exemestane, tamoxifen, survey, questionnaire, geriatric

More Information

Contact(s): Meagan Miller - aey8fc@uvahealth.org

Principal Investigator:

Phase: PHASE3

IRB

Number:

System ID: NCT06507618
